Design and Synthesis of α-Aryloxy-α-methylhydrocinnamic Acids: A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/ γ Agonists

Journal of Medicinal Chemistry

Volumn 47, Issue 10, 2004, Pages 2422-2425

  Xu, Yanping ^a   Rito, Christopher J ^a   Etgen, Garret J ^a   Ardecky, Robert J ^b   Bean, James S ^a   Bensch, William R ^a   Bosley, Jacob R ^a   Broderick, Carol L ^a   Brooks, Dawn A ^a   Dominianni, Samuel J ^a   Hahn, Patric J ^a   Liu, Sha ^b   Mais, Dale E ^b   Montrose Rafizadeh, Chahrzad ^a   Ogilvie, Kathy M ^b   Oldham, Brian A ^a   Peters, Mary ^a   Rungta, Deepa K ^b   Shuker, Anthony J ^a   Stephenson, Gregory A ^a   Tripp, Allie E ^a   Wilson, Sarah B ^a   Winneroski, Leonard L ^a   Zink, Richard ^a   Kauffman, Raymond F ^a   McCarthy, James R ^a   more..

^a ELI LILLY AND COMPANY   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIMETHYL 2 PHENYLACETIC ACID; 2 METHYL 3 [4 [2 (5 METHYL 2 THIOPHEN 2 YLOXAZOL 4 YL)ETHOXY]PHENYL] 2 PHENOXYPROPIONIC ACID; COUMARIC ACID; GLUCOSE; INSULIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; DYSLIPIDEMIA; HYPERGLYCEMIA; INSULIN SENSITIVITY; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANIMALS; ANTILIPEMIC AGENTS; BINDING, COMPETITIVE; CELL LINE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; PHENYLPROPIONATES; RADIOLIGAND ASSAY; RATS; RATS, ZUCKER; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES; TRANSCRIPTION FACTORS;

EID: 2342628600     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0342616     Document Type: Article

References (47)

1. Amos, A. F.; McCarty, D. J.; Zimmet, P. The rising global burden of diabetes and its complications: estimates and projections by 2010. Diabetes Metab. 1997, 14 (Suppl. 5), S5-S85.
2. (a) UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1996, 352, 837-853.
3. (b) Wei, M.; Gaskill, S. P.; Haffner, S. M.; Stern, M. P. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998, 7, 1167-1172.
4. (c) Ebara, T.; Conde, K.; Kako, Y.; Liu, Y.; Xu, Y.; Ramakrishnan, R.; Goldberg, I. J.; Shachter, N. S. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J. Clin. Invest. 2000, 105, 1807-1818.
5. (d) Ginsberg, H. N. Insulin resistance and cardiovascular disease. J. Clin. Invest. 2000,106, 453-458.
6. (d) Knuiman, M. W.; Welborn, T. A.; McCann, V. J.; Stanton, K. G.; Constable, L. J. Prevalance of Diabetic Complications in Relation to Risk Factors. Diabetes 1986, 35, 1332-1339.
7. (e) Feldt-Rasmussen, B.; Mathiesen, E.; Deckert, T. Effect of Two Years of Strict Metabolic Control on Progression of Incipient Nephropathy in Insulin-Dependent Diabetes. Lancet 1986, 2, 1300-1304.
8. (f) Dahl-Jorgensen, K.; Brinchmann-Hansen, O.; Hanssen, K. F.; Ganes, T. ; Kierulf, P.; Smeland, E.; Sandvik, L.; Agagenaes, O. Effect of Near-Normoglycemia for Two Years on Progression of Early Diabetic Retinopathy, Nephropathy, and Neuropathy: The Oslo Study. Br. Med. J. 1986, 293, 1195-1199.
9. Gerich, J. E. Oral Hypoglycemic Agents. N. Engl. J. Med. 1989, 321, 1231-1245.
10. (a) Hauner, H. The mode of action of thiazolidinediones. Diabetes Metab. Res. Rev. 2002, 18, S10-S15.
11. (b) Smith, U. Pioglitazone: mechanism of action. Int. J. Clin. Pract. 2001, Suppl. 121, 13-18.
12. (c) Bailey, C. J.; Day, C. Thiazolidinediones today. Br. J. Diabetes Vasc. Dis. 2001, 1, 7-13.
13. Lenhard, J. M. PPARγ/RXR as a molecular target for diabetes. Recept. Channels 2001, 249-258.
14. (a) Mangelsdorf, D. J.; Evans, R. M. The RXR heterodimers and orphan receptors. Cell 1995, 83, 841-850.
15. (b) Green, S.; Wahli, W. Peroxisome proliferator-activated receptors: finding the orphan a home. Mol. Cell. Endocrinol. 1994, 100, 149-153.
16. (a) Dreyer, C.; Krey, G.; Keller, H.; Givel, F.; Helftenbein, G.; Wahli, W. Control of the Peroxisomal β-Oxidation Pathway by a Novel Family of Nuclear Hormone Receptors. Cell 1992, 68, 879-887.
17. (b) Kliewer, S. A.; Xu, H. E.; Lambert, M. H.; Willson, T. M. Peroxisome Proliferator-Activated Receptors: From Genes to Physiology. Recent Prog. Horm. Res. 2001, 56, 239-263.
18. (c) Berger, J.; Moller, D. E. The Mechanism of Action of PPARs. Annu. Rev. Med. 2002, 53, 409-435.
19. (a) Tong, Q.; Hotamisligil, G. S. Molecular Mechanism of Adipocyte Differentiation. Endocr. Metab. Disord. 2001, 2, 349-355.
20. (b) Rose, E. D.; Walkey, C. J.; Puigserver, P.; Spiegelman, B. M. Transcriptional regulation of adipogenesis. Genes Dev. 2000, 14, 1293-1307.
21. Torra, I. P.; Gervois, P.; Staels, B. Peroxisome Proliferator-Activated Receptor alpha in Metabolic Disease, Inflammation, Atherosclerosis and Aging. Curr. Opin. Lipidol. 1999, 10, 151-159.
22. Frick, M. H.; Elo, O.; Haapa, K.; Heinonen, O. P.; Heinsalmi, P.; Helo, P.; Huttunen, J. K.; Kaitaniemi, P.; Koskinen, P.; Manninen, V.; Maenpaa, H.; Malkonen, M.; Manttari, M.; Norola, S.; Pasternack, A.; Pikkarainen, J.; Romo, M.; Sjoblom, T.; Nikkila, E. A. Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia. N. Engl. J. Med. 1986, 314, 488.
23. Kaneko, T.; Fujii, S.; Matsumoto, A.; Goto, D.; Ishimori, N.; Watano, K. ; Furumoto, T.; Sugawara, T.; Sobel, B. E.; Kitabatake, A. Induction of Plasminogen Activator Inhibitor-1 Endothelial Cells by Basic Fibroblast Growth Factor and Its Modulation by Fibric Acid. Arterioscler., Thromb., Vasc. Biol. 2002, 22, 855.
24. (a) Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R. The PPARs: From Orphan Receptors to Drug Discovery. J. Med. Chem. 2000, 43, 527.
25. (b) Berger, J.; Moller, D. E. The Mechanism of Action of PPARs. Annu. Rev. Med. 2002, 53, 409.
26. (a) Seedorf, U.; Assmann, G. The Role of PPARα in Obesity. Nutr. Metab. Cardiovasc. Dis. 2001, 11, 189.
27. (b) Youssef, J. A.; Badr, M. Z. Peroxisome Proliferator-Activated Receptors From Orphanage to Fame in a Decade. Saudi Pharm. J. 2001, 9, 1.
28. (c) Kersten, S. Peroxisome proliferator activated receptors and obesity. Eur. J. Phamacol. 2002, 440, 223.
29. (a) Rushforth, N. B.; Miller, N.; Bennett, P. H. Fasting and Two-Hour Post-Load Glucose Levels for the Diagnosis of Diabetes. The Relationship between Glucose Levels and Complications of Diabetes in the Pima Indians. Diabeologia 1979, 16, 373-379.
30. (b) Knuiman, M. W.; Welborn, T. A.; McCann, V. J.; Stanton, K. G.; Constable, L. J. Prevalence of Diabetic Complications in Relation to Risk Factors. Diabetes 1986, 35, 1332-1339.
31. (a) Feldt-Rasmussen, B.; Mathiesen, E.; Deckert, T. Effect of Two Years of Strict Metabolic Control on Progression of Incipient Nephropathy in Insulin-Dependent Diabetes. Lancet 1986, 2, 1300-1304.
32. (b) Dahl-Jorgensen, K.; Brinchmann-Hansen, O.; Hanssen, K. F.; Ganes, T. ; Kierulf, P.; Smeland, E.; Sandvik, L.; Agagenaes, O. Effect of Near-Normoglycemia for Two Years on Progression of Early Diabetic Retinopathy, Nephropathy, and Neuropathy: The Oslo Study. Br. Med. J. 1986, 293, 1195-1199.
33. (c) Pirart, J. Diabetes Mellitus and Its Degenerative Complications. A Prospective Study of 4,400 Patients Observed between 1947 and 1973. Diabetes Care 1978, 1, 168-188.
34. (d) Pirart, J. Diabetes Mellitus and Its Degenerative Complications. A Prospective Study of 4,400 Patients Observed between 1947 and 1973. Diabetes Care 1978, 1, 252-263.
35. (a) Nomura, M.; Kinoshita, S.; Satoh, H.; Maeda, T.; Murakami, K.; Tsunoda, M.; Miyachi, H.; Awana, K. (3-Substituted benzyl)-thiazolidine-2,4-diones as structurally new antihyperglycemic agents. Bioorg. Med. Chem. Lett. 1999, 9, 533-538.
36. (b) Lohray, B. B.; Lohray, V. B.; Bajji, A. C.; Kalchar, S.; Poondra, R. R.; Padakanti, S.; Chakrabarti, R.; Vikramadithyan, R. K.; Misra, P.; Juluri, S.; Mamidi, N. V.; Rajagopalan, R. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: A Dual PPAR Agonist with Potent Antihyperglycemic and Lipid Modulating Activity. J. Med. Chem. 2001, 44, 2675-2678.
37. (c) Brooks, D. A.; Etgen, G. J.; Rito, C. J.; Shuker, A. J.; Dominianni, S. J.; Warshawsky, A. M.; Ardecky, R.; Paterniti, J. R.; Tyhonas, J.; Karanewsky, D. S.; Kauffman, R. F.; Broderick, C. L.; Oldham, B. A.; Montrose-Rafizadeh, C.; Winneroski, L. L.; Faul, M. M.; McCarthy, J. R. Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]-propionic acids: a new class of dual PPAR α/γ agonists. J. Med. Chem. 2001, 44, 2061-2064.
38. (d) Desai, R. C.; Han, W.; Metzger, E. J.; Bergman, J. P.; Gratale, D. F.; MacNaul, K. L.; Berger, J. P.; Doebber, T. W.; Leung, K.; Moller, D. E.; Heck, J. V.; Sahoo, S. P. 5-Aryl thiazolidine-2,4-diones: discovery of PPAR dual α/γ agonists as antidiabetic agents. Bioorg. Med. Chem. Lett. 2003, 13, 2795-2798.
39. (e) Desai, R. C.; Gratale, D. F.; Han, W.; Koyama, H.; Metzger, E. J.; Lombardo, V. K.; MacNaul, K. L.; Doebber, T. W.; Berger, J. P.; Leung, K.; Franklin, R.; Moller, D. E.; Heck, J. V.; Sahoo, S. P. Aryloxazolidinediones: identification of potent orally active PPAR dual α/γ agonists. Bioorg. Med. Chem. Lett. 2003, 13, 3541-3544.
40. (f) Sauerberg, P.; Pettersson, I.; Jeppesen, L.; Bury, P. S.; Mogensen, J. P.; Wasserman, K.; Brand, C. L.; Sturis, J.; Woeldike, H. F.; Fleckner, J.; Andersen, A.-S. T.; Mortensen, S. B.; Svensson, L. A.; Rasmussen, H. B.; Lehmann, S. V.; Polivka, Z.; Snidelar, K.; Panajotova, V.; Ynddal, L.; Wulff, E. M. Novel Tricyclic-a-alkyloxyphenylpropionic Acids: Dual PPAR α/γ Agonists with Hypolipidemic and Antidiabetic Activity. J. Med. Chem. 2002, 45, 789-804.
41. (g) Ebdrup, S.; Pettersson, I.; Rasmussen, H. B.; Deussen, H.-J.; Jensen, A. F.; Mortensen, S. B.; Fleckner, J.; Pridal, L.; Nygaard, L.; Sauerberg, P. Synthesis and Biological and Structural Characterization of the Dual-Acting Peroxisome Proliferator-Activated Receptor α/γ Agonist Ragaglitazar. J. Med. Chem. 2003, 46, 1306-1317.
42. Synthesis of the alcohol precursors to tosylates 6a-e: Godfrey, A. G.; Brooks, D. A.; Hay, L. A.; Peters, M.; McCarthy, J. R.; Mitchell, D. Application of the Dakin-West reaction for the synthesis of oxazole-containing dual PPARα/γ agonists. J. Org. Chem. 2003, 68, 2623-2632.
43. (a) Lilly, Eli and Co. GB 1176339, 1970.
44. (b) Kennard, C. H.; Smith, G.; White, A. H. Acta Crystallogr., Sect. B 1981, 1314-1317.
45. Brooks, D. A.; Connor, S. E.; Dominianni, S. J.; Godfrey, A. G.; Gossett, L. S.; Rito, C. J.; Tripp, A. E.; Warshawsky, A. M.; Winneroski, L. L.; Zhu, G. Oxazolyl-aryloxyacetic acid derivatives and thiazole analogs and their uses as PPAR agonists, e.g., as antidiabetics and hypolipidemics. WO 2002018355, 2002.
46. (a) Keller, H. J.; Devchand, P. R.; Perroud, M.; Wahli, W. PPARα structure-functional relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol. Chem. Hoppe-Seyler 1997, 378, 651-655. (b) Lewis, D. F. V.; Jacobs, M. N.; Lake, B. G. Molecular modeling of the peroxisome proliferator-activated receptor α. (PPARα) from human, rat and mouse, based on homology with the human PPARγ crystal structure. Toxicol. in Vitro 2002, 16, 275-280.
47. (a) Keller, H. J.; Devchand, P. R.; Perroud, M.; Wahli, W. PPARα structure-functional relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol. Chem. Hoppe-Seyler 1997, 378, 651-655. (b) Lewis, D. F. V.; Jacobs, M. N.; Lake, B. G. Molecular modeling of the peroxisome proliferator-activated receptor α. (PPARα) from human, rat and mouse, based on homology with the human PPARγ crystal structure. Toxicol. in Vitro 2002, 16, 275-280.